These awards represent a partnership between Merck Animal Health and the Global Alliance for Rabies Control (GARC), a nonprofit group dedicated to preventing human deaths from rabies and relieving the burden of rabies in other animal populations. Most importantly, these awards will help raise global awareness for rabies champions in an effort to strengthen their support on an international level.
“Rabies is responsible for an estimated 59,000 deaths each year, many are children under the age of 15 and almost all of those deaths from dog bites,” states Alasdair King, director, Intergovernmental Veterinary Health, Merck Animal Health. “We are proud to partner with GARC to recognize those who are working tirelessly to put an end to the spread of this disease, making communities safer for all.”
This year, eight awards will be presented to recipients around the world who are actively contributing to the prevention and control of rabies and are demonstrating an impact in their community.
Winners will receive US$1,200 (or resources of equal value). Nominations can be submitted until August 7th, 2017 at https://rabiesalliance.org/world-rabies-day/awards. Winners will be announced on September 28th, World Rabies Day.
To learn more about the Global Alliance for Rabies Control, visit https://rabiesalliance.org/.
About Merck Animal Health
For more than a century, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn, Facebook and Twitter at @MerckAH.
About the Global Alliance for Rabies Control
The Global Alliance for Rabies Control (GARC) is a leading non-profit organisation that aims to eliminate deaths from canine rabies by 2030, by working with governments, veterinary, public health and educational experts and communities to facilitate policy change and build capacity to eliminate rabies in areas hardest hit by the disease.
For more information about rabies and GARC’s work, visit http://rabiesalliance.org.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2016 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
